Across TCGA pan-cancer cohorts, EVI2B mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated EVI2B data layer compared with 25 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher EVI2B mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated EVI2B expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

COAD, LUAD, and LSCC are the cancer types where EVI2B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Median	All	0.887	1.000	.040	6	view →
LUAD	DFS	Quartile	II,III,IV	0.881	0.394	.038	4	view →
LSCC	OS	Median	II,III,IV	0.617	0.853	.032	2	view →
PDAC	DFS	Quartile	II,III,IV	0.602	0.903	.035	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: EVI2B tumor-vs-normal RNA expression · all EVI2B data types